227 related articles for article (PubMed ID: 7481839)
1. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
Heinemann V; Schulz L; Issels RD; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):11-8. PubMed ID: 7481839
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
3. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
4. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
[TBL] [Abstract][Full Text] [Related]
5. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
6. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
Mol Pharmacol; 1990 Oct; 38(4):567-72. PubMed ID: 2233693
[TBL] [Abstract][Full Text] [Related]
8. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
[TBL] [Abstract][Full Text] [Related]
9. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang P; Chubb S; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1991 Nov; 51(22):6110-7. PubMed ID: 1718594
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett W; Huang P; Searcy CE; Gandhi V
Semin Oncol; 1996 Oct; 23(5 Suppl 10):3-15. PubMed ID: 8893876
[TBL] [Abstract][Full Text] [Related]
11. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
Van Moorsel CJ; Smid K; Voorn DA; Bergman AM; Pinedo HM; Peters GJ
Int J Oncol; 2003 Jan; 22(1):201-7. PubMed ID: 12469205
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of 3-deazauridine in tumor cells sensitive and resistant to arabinosylcytosine.
Brockman RW; Shaddix SC; Williams M; Nelson JA; Rose LM; Schabel FM
Ann N Y Acad Sci; 1975 Aug; 255():501-21. PubMed ID: 171997
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Potent Inhibition of CTP Synthase by Gemcitabine-5'-Triphosphate.
McCluskey GD; Mohamady S; Taylor SD; Bearne SL
Chembiochem; 2016 Dec; 17(23):2240-2249. PubMed ID: 27643605
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
15. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
16. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
Ross DD; Cuddy DP
Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
[TBL] [Abstract][Full Text] [Related]
17. In situ regulation of mammalian CTP synthetase by allosteric inhibition.
Aronow B; Ullman B
J Biol Chem; 1987 Apr; 262(11):5106-12. PubMed ID: 2435724
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
19. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]